$Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia$

Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia

Saved in:

Bibliographic Details
Main Authors:	Christine E. Ryan, Yue Ren, Svitlana Tyekucheva, Jon E. Arnason, Adam M. Boruchov, Caron A. Jacobson, David C. Fisher, Hari Miskin, Peter Sportelli, Jennifer R. Brown, Matthew S. Davids
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	HemaSphere
Online Access:	https://doi.org/10.1002/hem3.70067
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse
by: Timothy S. Oh, et al.
Published: (2022-01-01)

Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
by: EA Stadnik, et al.
Published: (2018-01-01)

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study
by: Trine Trab, et al.
Published: (2025-08-01)

Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
by: EA Nikitin, et al.
Published: (2017-07-01)

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
by: Carsten U. Niemann, et al.
Published: (2025-08-01)

Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice
by: VI Vorob’ev, et al.
Published: (2019-03-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients
by: NV Kurkina, et al.
Published: (2019-05-01)

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia
by: James T. Yoon, et al.
Published: (2025-06-01)

MAMDC2‐AS1 Induces Cuproptosis in Relapsed and Refractory Multiple Myeloma
by: Yifei Chen, et al.
Published: (2025-05-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

How to use ibrutinib
by: Е. А. Nikitin, et al.
Published: (2017-04-01)

Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia
by: Bingqian Jiang, et al.
Published: (2025-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review
by: Donato Mannina, et al.
Published: (2017-01-01)

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576
by: Januario E. Castro, et al.
Published: (2022-01-01)

Drug review: Ibrutinib
by: Parathan Karunakaran
Published: (2020-01-01)

Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis
by: Joseph Pidala, et al.
Published: (2025-03-01)

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
by: Lawrence G Lum, et al.
Published: (2025-01-01)

Treatment efficacy for relapsed/refractory multiple myeloma patients with gain/amplification of 1q21
by: Xia Zhou, et al.
Published: (2025-04-01)

Ibrutinib-associated osteonecrosis of the jaw
by: Annu Singh, et al.
Published: (2024-03-01)

Ibrutinib and Neurolisteriosis: Simple Coincidence?
by: Paul Dalmas, et al.
Published: (2024-06-01)

Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma
by: Christiane Querfeld, et al.
Published: (2025-05-01)

Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study
by: Tae Min Kim, et al.
Published: (2025-04-01)

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
by: Isla M. Johnson, et al.
Published: (2025-02-01)

Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia
by: Hui-Sheng Zhou, et al.
Published: (2025-04-01)

Impact of Hematopoietic Stem Cell Transplantation on PD-1 Blockade Efficacy in Relapsed/Refractory Hodgkin’s Lymphoma
by: Filomena Emanuela Laddaga, et al.
Published: (2025-04-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

Current management of relapsed/refractory immune thrombocytopenia
by: Alina Mititelu, et al.
Published: (2023-01-01)

Relapsing Polychondritis with Meningoencephalitis Refractory to Immunosuppressant Therapy
by: Mohammad Mousbah Al-Tabbaa, et al.
Published: (2018-01-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Profound Sinoatrial Arrest Associated with Ibrutinib
by: Kanupriya Mathur, et al.
Published: (2017-01-01)

Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study
by: Ya. V. Krylova, et al.
Published: (2024-09-01)

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study
by: Gabriel Brisou, et al.
Published: (2025-05-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia
by: Yesid Alvarado-Valero, et al.
Published: (2025-08-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Teclistamab for heavily pretreated relapsed / refractory POEMS syndrome
by: Alexis Talbot, et al.
Published: (2025-07-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01)

Treatment of pediatric relapsed and refractory acute myeloid leukemia
by: F. A. Makhacheva, et al.
Published: (2023-05-01)